We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 628

A summary of major developments in key areas - general counsel update - July 2014
  • Herbert Smith Freehills LLP
  • Australia, European Union, Hong Kong, United Kingdom
  • July 15 2014

Legislation, in the form of a Regulation and Directive, has been published in the Official Journal of the European Union which will substantially


Johnson & JohnsonNovartis another challenge to pay for delay: is this ever permissible?
  • Bryan Cave LLP
  • European Union, France, Germany, Italy, United Kingdom
  • January 14 2014

In the latest challenge to so-called “pay for delay” or “reverse payment” agreements, on 10 December 2013, the European Commission fined the


Indemnity arrangements for healthcare professionals: long overdue
  • Kennedys Law LLP
  • European Union, United Kingdom
  • July 26 2013

The Department of Health's consultation on the implementation of the Health Care and Associated Professions (Indemnity Arrangements) Order 2013 (the


Sidley Austin LLP global pricing newsletter - volume three 2014
  • Sidley Austin LLP
  • Brazil, Canada, China, European Union, France, Germany, India, United Kingdom, USA
  • April 15 2014

On October 21, 2013, Brazil’s National Agency of Supplemental Health enacted Normative Resolution 388, which mandated that all private healthcare


EC-funded research suggests approach to insuring nanomaterial production risk
  • Shook Hardy & Bacon LLP
  • European Union
  • April 5 2013

In a Nature Nanotechnology commentary titled "The insurability of nanomaterial product risk," business and scientific researchers funded by the


Actualidad Normativa N.º 8
  • Gómez-Acebo & Pombo Abogados
  • European Union, Spain
  • July 21 2014

En materia medioambiental consideramos de interés las siguientes normas: El Real Decreto 1632014, de 14 de marzo, por el que se crea el Registro de


Draft regulation on clinical trials - abolishment of obligatory insurance
  • Bird & Bird
  • European Union
  • February 25 2013

In July 2012 the European Commission published its proposal for a "Regulation on clinical trials on medicinal products for human use" (COM 2012 369


Canada-Europe Free Trade Agreement: a new prescription for drug patents in Canada
  • DLA Piper LLP
  • Canada, European Union
  • October 31 2013

On October 17, Canadian Prime Minister Stephen Harper flew to Brussels to conclude a Comprehensive Economic and Trade Agreement ("CETA"), or free


Food companies should revisit insurance program and other risk management in light of emerging massive European Union E.coli outbreak
  • Stoel Rives LLP
  • European Union
  • June 1 2011

The E. coli outbreak unraveling now in the European Union, centered primarily in Germany, is setting new records for both the number of affected persons and the number of persons diagnosed with Hemolytic Uremic Syndrome (HUS), a serious complication from E. coli infection (HUS can lead to kidney failure, brain damage and death


European Court of Justice considers the validity of Flemish legislation limiting eligibility to a care insurance scheme
  • Locke Lord LLP
  • Belgium, European Union
  • April 10 2008

In Government of the French Community, and Walloon Government v Flemish Government Case C-21206, ECJ (Grand Chamber), the European Court of Justice (ECJ) determined that Flemish legislation limiting eligibility to a care insurance scheme was contrary to European provisions concerning the right to freedom of movement within the European Community (EC) in so far as the care insurance scheme included a residence requirement that excluded persons who worked in the Flemish region or in the bilingual Brussels-Capital, but who resided in another part of the national territory (ie the French or German speaking region